ROCHE WILL CO-MARKET AMGEN's NEUPOGEN (G-CSF) IN EUROPE
ROCHE WILL CO-MARKET AMGEN's NEUPOGEN (G-CSF) IN EUROPE under an agreement announced Sept. 28. "Upon launch, the product will be sold under the Amgen trademark by sales forces of both companies," the two companies stated in a joint press release. Amgen said it will begin building a European sales force, which will be operational at the time of product's anticipated 1991 launch. Licensing applications are planned for both the European Economic Community and the U.S. in 1989, the biotech firm noted. The recombinant granulocyte colony stimulating factor, currently in Phase III trials, is being studied in patients with various types of cancer. The hormone is potentially useful in immune-compromised patients, Amgen explained, because it stimulates the production of neutrophils, a class of white blood cells that defend the body against bacterial infection. Neupogen is likely to be the second Amgen product to reach the European market. The first, erythropoietin, was recently approved in Switzerland for treatment of anemia in patients with end-stage renal disease. The new Amgen European sales force will not market recombinant erythropoietin; J&J subsidiary Cilag has exclusive European rights to the product. In Europe, erythropoietin is marketed under the (ITALICS)Eprex brand. Amgen Chairman George Rathmann called the agreement "a significant milestone" for the company that will establish Amgen's operational base for entry into Europe. "With an outstanding partner in Hoffmann-LaRoche, we are assured of an aggressive European launch for this major therapeutic product," he added.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth